Liquid Biopsy + Artificial Intelligence= New Approach to Cancer
November 7, 2017 | Terry Sharrer
News about new liquid biopsy studies is snowballing, but the lagging edge is in the interpretation of the genomic data. SOPHiA Genetics (Saint Sulpice, Switzerland) claims it has a highly accurate algorithm for interpreting DNA data from circulating tumors in blood, urine or cerebral spinal fluid. The company also asserts that “a liquid biopsy tends to be more accurate than a tissue biopsy as it offers a more comprehensive picture of the spread or remission of a cancer.” It is unclear if this artificial intelligence software is FDA approved in the US, but it is being used in more than 300 European care providers. MORE
Image Credit: SOPHiA Genetics